Cryo-Cell International EBIT

As of the most recent data (August 2026), CCEL shows a EBIT of $-2.1M. That compares with $2.7M in the prior-year period — down 176.5% year over year. That is below the Healthcare sector average of $1.9T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CCEL's EBIT is now $-2.1M (was $2.7M) — a 176.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cryo-Cell International is outperforming or lagging.

The Healthcare sector average EBIT is about $1.9T. Cryo-Cell International is at $-2.1M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how CCEL stacks up against individual peers as well.

Tracking CCEL's ebit over time shows whether Cryo-Cell International is scaling, shrinking, or reshaping that part of the business. The current reading is $-2.1M That compares with $2.7M in the prior-year period — down 176.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Cryo-Cell International's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-2.1M) with ownership activity and broader fundamentals.